Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Moricizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | NR1I3 | Q14994 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moricizine SCHEMBL41358 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL9447065 | 0.99 | LMNA (0.98) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL29599149 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL16794 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL1650461 | 0.97 | CYP3A4 (0.97) | LMNAMEN1KMT2AGAAMAPK1 | |
| SCHEMBL15913933 | 0.88 | CYP3A4 (0.80) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL2430390 | 0.87 | CYP3A4 (0.78) | LMNAMEN1KMT2AGAAMAPK1 | |
| SCHEMBL19225040 | 0.84 | NR1I3 (1.00) | LMNAMEN1KMT2AGAAMAPK1 | |
| SCHEMBL9446980 | 0.83 | LMNA (0.72) | LMNAMEN1KMT2AGAAMAPK1 | |
| Moricizine SCHEMBL28086262 | 0.83 | CYP3A4 (0.70) | LMNAMEN1KMT2AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192786-A1 | STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA LLC (US) | 2023-06-22 | — | — | US | claimed |
| US-20210393597-A1 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | US | claimed |
| WO-2021232067-A1 | STATS3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA, LLC (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-11-11 | — | — | US | claimed |
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-17 | — | — | US | claimed |
| US-20200230135-A1 | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-23 | — | — | US | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| WO-2019023525-A1 | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-31 | — | — | WO | claimed |
| WO-2018183908-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-10-04 | — | — | WO | claimed |
| CN-106265686-A | The pharmaceutical composition of Moracizine Hydrochloride and the application in biological medicine thereof | 赵浩浩 | 2017-01-04 | — | — | CN | claimed |
| EP-2827884-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | Trustees Of Tufts College (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013185764-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA (DK) | 2013-12-19 | — | — | WO | claimed |
| WO-2013142119-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| WO-2013142611-A2 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| US-8445517-B2 | Stat modulators | DANA-FARBER CANCER INSTITUTE (US) | 2013-05-21 | — | — | US | claimed |
| US-20110144043-A1 | Stat modulators | DANA-FARBER CANCER INSTITUTE (US) | 2011-06-16 | — | — | US | claimed |
| WO-2008156644-A2 | STAT MODULATORS | FRANK DAVID A (US) | 2008-12-24 | — | — | WO | claimed |
| CN-1562039-A | Moricizine hydrochloride dripping pill and its preparing method | HONGYI TECH CO LTD NANCHAN (CN) | 2005-01-12 | — | — | CN | claimed |
| WO-1993010108-A1 | PROCESS FOR THE PREPARATION OF MORICIZINE HYDROCHLORIDE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| US-5202435-A | Reacting ethanol solution of moricizine with hydrochloric acid at specified molar ratio | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | SLC11A2, BRCA1, RNASE1 | LMNA 2391/4885MEN1 947/4885KMT2A 459/4885 |
| US-20110144043-A1 | Stat modulators | STAT1, STAT5A, STAT5B | LMNA 4649/4885MEN1 4232/4885KMT2A 1464/4885 |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | CD47, CD74, HAVCR2 | LMNA 3906/4885MEN1 2907/4885KMT2A 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.